These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States. Kelly SP; Anderson WF; Rosenberg PS; Cook MB Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421 [TBL] [Abstract][Full Text] [Related]
5. Trends for Stage and Grade Group of Prostate Cancer in the US (2010-2016). Schmanke K; Okut H; Ablah E Urology; 2021 Mar; 149():110-116. PubMed ID: 33227304 [TBL] [Abstract][Full Text] [Related]
6. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database. Bandini M; Mazzone E; Preisser F; Nazzani S; Zaffuto E; Marchioni M; Tian Z; Pompe RS; Tilki D; Graefen M; Shariat SF; Montorsi F; Saad F; Briganti A; Karakiewicz P Eur Urol Oncol; 2018 Sep; 1(4):314-320. PubMed ID: 31100253 [TBL] [Abstract][Full Text] [Related]
7. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. Butler SS; Muralidhar V; Zhao SG; Sanford NN; Franco I; Fullerton ZH; Chavez J; D'Amico AV; Feng FY; Rebbeck TR; Nguyen PL; Mahal BA Cancer; 2020 Feb; 126(4):717-724. PubMed ID: 31794057 [TBL] [Abstract][Full Text] [Related]
8. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083 [TBL] [Abstract][Full Text] [Related]
10. Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013. Houston KA; King J; Li J; Jemal A J Urol; 2018 Mar; 199(3):676-682. PubMed ID: 28965781 [TBL] [Abstract][Full Text] [Related]
11. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening. Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117 [TBL] [Abstract][Full Text] [Related]
12. Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017. Cao Y; Zhang W; Li Y; Fu J; Li H; Li X; Gao X; Zhang K; Liu S Prostate; 2021 Oct; 81(14):1071-1077. PubMed ID: 34320230 [TBL] [Abstract][Full Text] [Related]
13. Trade-Off between Treatment of Early Prostate Cancer and Incidence of Advanced Prostate Cancer in the Prostate Screening Era. Shen X; Kumar P J Urol; 2016 May; 195(5):1397-1402. PubMed ID: 26656266 [TBL] [Abstract][Full Text] [Related]
14. Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics. Welch HG; Gorski DH; Albertsen PC N Engl J Med; 2015 Oct; 373(18):1685-7. PubMed ID: 26510017 [No Abstract] [Full Text] [Related]
15. Recent Changes in Prostate Cancer Screening Practices and Epidemiology. Lee DJ; Mallin K; Graves AJ; Chang SS; Penson DF; Resnick MJ; Barocas DA J Urol; 2017 Dec; 198(6):1230-1240. PubMed ID: 28552708 [TBL] [Abstract][Full Text] [Related]
16. Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing. Shoag J; Halpern JA; Lee DJ; Mittal S; Ballman KV; Barbieri CE; Hu JC J Urol; 2016 Oct; 196(4):1047-52. PubMed ID: 27060052 [TBL] [Abstract][Full Text] [Related]
17. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. Welch HG; Albertsen PC J Natl Cancer Inst; 2009 Oct; 101(19):1325-9. PubMed ID: 19720969 [TBL] [Abstract][Full Text] [Related]
18. The role of increasing detection in the rising incidence of prostate cancer. Potosky AL; Miller BA; Albertsen PC; Kramer BS JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782 [TBL] [Abstract][Full Text] [Related]
19. Is prostate cancer different in black men? Answers from 3 natural history models. Tsodikov A; Gulati R; de Carvalho TM; Heijnsdijk EAM; Hunter-Merrill RA; Mariotto AB; de Koning HJ; Etzioni R Cancer; 2017 Jun; 123(12):2312-2319. PubMed ID: 28436011 [TBL] [Abstract][Full Text] [Related]
20. Metastatic prostate cancer incidence in Australia after amendment to prostate-specific antigen screening guidelines. Smith S; Wolanski P ANZ J Surg; 2018; 88(7-8):E589-E593. PubMed ID: 29194902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]